- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-691/13: Judgment of the Court (Third Chamber) of 26 February 2015 (request for a preliminary ruling from the Conseil d'État — France) — Les Laboratoires Servier SA v Ministre des Affaires sociales et de la Santé, Ministre de l’Économie et des Finances (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(2) — Establishment of a list of medicinal products reimbursed by the health insurance funds — Amendment of the conditions of reimbursement of a medicinal product when renewing its inclusion in such a list — Obligation to state reasons)
ECLI:EU:UNKNOWN:62013CA0691
62013CA0691
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
27.4.2015
Official Journal of the European Union
C 138/17
(Case C-691/13) (<span class="super">1</span>)
((Reference for a preliminary ruling - Medicinal products for human use - Directive 89/105/EEC - Article 6(2) - Establishment of a list of medicinal products reimbursed by the health insurance funds - Amendment of the conditions of reimbursement of a medicinal product when renewing its inclusion in such a list - Obligation to state reasons))
(2015/C 138/22)
Language of the case: French
Referring court
Parties to the main proceedings
Applicant: Les Laboratoires Servier SA
Defendant: Ministre des Affaires sociales et de la Santé, Ministre de l’Économie et des Finances
Operative part of the judgment
Article 6(2) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that the obligation to state reasons set out in that provision is applicable to a decision which reinstates a product in the list of medicinal products covered by the health insurance system, but which limits the reimbursement of that product to a specific category of patients.
(<span class="note">1</span>) OJ C 85, 22.3.2014.